Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 5/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KYAT1 | Q16773 | 5/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23354896 | 1.00 | NPSR1 (0.57) | NPSR1GAAALOX12MAPTKYAT1 | |
| SCHEMBL23354894 | 1.00 | NPSR1 (0.57) | NPSR1GAAALOX12MAPTKYAT1 | |
| SCHEMBL23367550 | 0.88 | NPSR1 (0.55) | NPSR1GAAALOX12MAPTKYAT1 | |
| SCHEMBL23354843 | 0.88 | NPSR1 (0.55) | NPSR1GAAALOX12MAPTKYAT1 | |
| SCHEMBL23354844 | 0.88 | NPSR1 (0.55) | NPSR1GAAALOX12MAPTKYAT1 | |
| SCHEMBL23354696 | 0.85 | MAPT (0.55) | NPSR1GAAALOX12MAPTKYAT1 | |
| SCHEMBL23367177 | 0.85 | MAPT (0.55) | NPSR1GAAALOX12MAPTKYAT1 | |
| SCHEMBL23367209 | 0.85 | KYAT1 (0.56) | NPSR1GAAMAPTKYAT1ATM | |
| SCHEMBL23354735 | 0.85 | KYAT1 (0.56) | NPSR1GAAMAPTKYAT1ATM | |
| SCHEMBL23354736 | 0.85 | KYAT1 (0.56) | NPSR1GAAMAPTKYAT1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2021094434-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822265-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer AG (DE) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | NPSR1 111/4885GAA 1454/4885ALOX12 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.